Co-existing Medical Conditions Research Articles

The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension.

Pulmonary hypertension (PH) is a progressive disorder characterized by a chronic in-crease in pulmonary arterial pressure, frequently resulting in right-sided heart failure and potentially death. Co-existing medical conditions are important factors in PH, since they not only result in the genesis of the disorder, but may also contribute to its progression. Various studies have assessed the impact of thyroid disorders and other endocrine conditions (namely estrogen exposure, obesity, and diabetes mellitus) on the progression of PH. The complex interactions that hormones may have with the cardiovascular system and pulmonary vascular bed can create several pathogenetic routes that could explain the effects of endocrine disorders on PH development and evolution. The aim of this review is to summarize current knowledge on the role of concomitant thyroid disorders, obesity, diabetes mellitus, and estrogen exposure as potential modifiers for PH, and especially for pulmonary arterial hypertension, and to discuss possible pathogenetic routes linking them with PH. This information could be valuable for practicing clinicians so as to better evaluate and/or treat concomitant endocrine conditions in the PH population.

ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions: Correction.

ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions: Correction.

ACOG Practice Bulletin No. 206 Summary: Use of Hormonal Contraception in Women With Coexisting Medical Conditions.

Although numerous studies have addressed the safety and effectiveness of hormonal contraceptive use in healthy women, data regarding women with underlying medical conditions or other special circumstances are limited. The U.S. Medical Eligibility Criteria (USMEC) for Contraceptive Use, 2016 (1), which has been endorsed by the American College of Obstetricians and Gynecologists, is a published guideline based on the best available evidence and expert opinion to help health care providers better care for women with chronic medical problems who need contraception. The goal of this Practice Bulletin is to explain how to use the USMEC rating system in clinical practice and to specifically discuss the rationale behind the ratings for various medical conditions. Contraception for women with human immunodeficiency virus (HIV) (2); the use of emergency contraception in women with medical coexisting medical conditions, including obesity, (3); and the effect of depot medroxyprogesterone acetate (DMPA) on bone health (4) are addressed in other documents from the American College of Obstetricians and Gynecologists.

ACOG Practice Bulletin No. 206: Use of Hormonal Contraception in Women With Coexisting Medical Conditions.

Although numerous studies have addressed the safety and effectiveness of hormonal contraceptive use in healthy women, data regarding women with underlying medical conditions or other special circumstances are limited. The U.S. Medical Eligibility Criteria (USMEC) for Contraceptive Use, 2016 (), which has been endorsed by the American College of Obstetricians and Gynecologists, is a published guideline based on the best available evidence and expert opinion to help health care providers better care for women with chronic medical problems who need contraception. The goal of this Practice Bulletin is to explain how to use the USMEC rating system in clinical practice and to specifically discuss the rationale behind the ratings for various medical conditions. Contraception for women with human immunodeficiency virus (HIV) (); the use of emergency contraception in women with medical coexisting medical conditions, including obesity, (); and the effect of depot medroxyprogesterone acetate (DMPA) on bone health () are addressed in other documents from the American College of Obstetricians and Gynecologists.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer.

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex disease that affects children and adolescents as well as adults. The etiology has not been established. While many pediatricians and other health-care providers are aware of ME/CFS, they often lack essential knowledge that is necessary for diagnosis and treatment. Many young patients experience symptoms for years before receiving a diagnosis. This primer, written by the International Writing Group for Pediatric ME/CFS, provides information necessary to understand, diagnose, and manage the symptoms of ME/CFS in children and adolescents. ME/CFS is characterized by overwhelming fatigue with a substantial loss of physical and mental stamina. Cardinal features are malaise and a worsening of symptoms following minimal physical or mental exertion. These post-exertional symptoms can persist for hours, days, or weeks and are not relieved by rest or sleep. Other symptoms include cognitive problems, unrefreshing or disturbed sleep, generalized or localized pain, lightheadedness, and additional symptoms in multiple organ systems. While some young patients can attend school, on a full or part-time basis, many others are wheelchair dependent, housebound, or bedbound. Prevalence estimates for pediatric ME/CFS vary from 0.1 to 0.5%. Because there is no diagnostic test for ME/CFS, diagnosis is purely clinical, based on the history and the exclusion of other fatiguing illnesses by physical examination and medical testing. Co-existing medical conditions including orthostatic intolerance (OI) are common. Successful management is based on determining the optimum balance of rest and activity to help prevent post-exertional symptom worsening. Medications are helpful to treat pain, insomnia, OI and other symptoms. The published literature on ME/CFS and specifically that describing the diagnosis and management of pediatric ME/CFS is very limited. Where published studies are lacking, recommendations are based on the clinical observations and practices of the authors.

Optimal Urine Protein-to-Creatinine Ratio in the Setting of Co-Existing Medical Conditions [3I

Optimal Urine Protein-to-Creatinine Ratio in the Setting of Co-Existing Medical Conditions [3I

Clinical charactheristics of late onset mania

Objective: Our aim is to compare demographic and clinical characteristics of patients with early and late-onset diagnosed as bipolar disorder type I (BPD-I) manic episode retrospectively. Method: A total of 24 elderly (?65 years old) hospitalized patients with bipolar disorder were divided into 2 groups as those with early-onset and late-onset disorder, according to a threshold of 50 years of age, and were retrospectively compared with 29 young patients (19-55 years old) in terms of sociodemographic characteristics, clinical symptoms, family history, prophylactic treatment, co-existing medical conditions, duration of hospitalization, psychiatric treatment, and clinical improvement. Results: A positive family history was also more prevalent in young patients and patients with early-onset disease. Co-existing medical conditions were more common in patients with late-onset disease. A positive correlation was found between the duration of education and duration of illness. Flight of ideas and pressured speech were more commonly observed in young patients and patients with early-onset disease. While delusions of erotomanic type were more frequent in young patients, persecution delusions were more common in elderly patients. In terms of treatment, valproate was preferred in the elderly patients and antipsychotic medications were more frequently used in late-onset elderly patients when compared to early-onset elderly patients. The duration of hospitalization was longer in elderly patients than younger ones. Conclusion: Our findings show that late-onset mania has different characteristics compared to early-onset mania in terms of clinical characteristics, symptom profile, family history, co-existing medical diseases, duration of hospitalization, and response to treatment. However, it is hard to conclude that it as a different clinical subgroup when previous studies about late-onset mania are taken into consideration. Further studies with adequate sample sizes are needed.

Co-existing mental and medical conditions among family medicine outpatients in a tertiary hospital in southern Nigeria

Background: A considerable number of patients seen in the Primary Care Clinics have co-morbid mental disorders with medical conditions that are largely not recognized by the primary care physician. This inability to recognize these mental disorders lead to non diagnosis and non treatment with eventual amplification of physical symptoms, low productivity at work and functional disability at home.Aims: To screen the patients attending the general outpatient clinic for anxiety and depression co-occurring with medical conditions.Methods: Two hundred and forty five patients aged 20 years and above attending the General Outpatient Clinic of the University of Uyo Teaching Hospital were randomly assessed for anxiety and depression using the Hospital Anxiety and Depression Scale (HADS). The level of caseness for anxiety and depression were determined using a HADS score of 8 and above. Their medical conditions were diagnosed and associations were determined with mental disorders (anxiety and depression).Results: A total of 36.7% of patients scored above cut off point of 8 on the anxiety subscale while 24.5% of the subjects scored above cut off point of 8 on the depression subscale. 24.1%, (n=59) scored 8-10 on the anxiety subscale of HADS which is interpreted to be mild anxiety, 11.0%, (n=27) scored 11-14 on the anxiety subscale of HADS which is interpreted to be moderate anxiety and 1.6%, (n=4) scored 15-21 on the anxiety subscale of HADS which is interpreted to be severe anxiety. Similarly, 15.9%, (n=39) scored 8-10 on the depression subscale of HADS which is interpreted to be mild depression, 7.8%, (n=19) scored 11-14 on the depression subscale of HADS which is interpreted to be moderate depression and 0.8%, (n=2) scored 15-21 on the depression subscale of HADS which is interpreted to be severe depression. Hypertension was present in 22.04%, (n=54) respondents with anxiety p = 0.016 and depression p=0.025. HIV/AIDS was present in 4.08%, (n=10) respondents with depression p = 0.006.Conclusion: The result of the study shows that patients attending general outpatients' clinic suffer from mental disorders like anxiety and depression which may co- exist with hypertension and HIV/AIDS. Therefore, a careful assessment of patients attending these clinics will detect these disorders and treatment will improve the physical condition of the patients.

855

Introduction: Pediatric Sedation Anesthesia- Outside Operating Room (PSA-OOR) is well described with overall low adverse events (AE) in certain settings. AE associated with PSA-OOR for Gastro-Intestinal procedures have been described in small single center studies with wide variance in outcomes. Predictors of such outcomes are unclear. Estimating the incidence of AE in children undergoing PSA-OOR for Esophagogastroduodenoscopy (EGD), Colonoscopy (Col), or both may help identify the predictors of AE. Methods: Retrospective analysis of prospectively collected EGD and Col data from Pediatric Sedation Research Consortium (PSRC) database, a web-based collaborative from 40 North American institutions (09/07-11/11). Primary outcome variable is any AE. Independent variables include-Age (5 Groups), gender, ASA status (S), procedure (only EGD, only Col, or both), medication used, location performed and presence of co-existing medical conditions (CMC). Descriptive statistics used to summarize the data. Using multivariable logistic regression model, odds ratio (OR), and 95% Confidence Intervals (CI) were computed for each independent variable. Results: 12030 procedures were performed (EGD 7970, Col 1378, both 2682), Variables include: age (Gp I: < 1y: 222; Gp II:1-5y: 2081; Gp III: > 5-10y: 3464; Gp IV: >10-15y: 428; Gp V: > 15y: 1978), male (51%), ASA (S1: 25.7%, S2: 67%, S3 or greater: 6.6%), with CMC (32%), in Sedation Unit (83%), and Propofol (97%). Overall incidence of any AE was 4.8% (582); the most common AE were persistent desats (1.5%), airway obstruction (1%), cough (0.9%) & laryngospasm (0.6%). No deaths or cardiopulmonary resuscitation (CPR). Age Group as AE % (Gp I: 35/222 (15.7%); Gp II: 162/2081 (7.8%); Gp III: 140/3464 (4%); Gp IV: 173/4285 (4%); Gp V: 72/1978 (3.6%)). Regression analysis revealed: age (Gp 1: 4.1 odds ratio (OR), 2.6-6.5, 95% confidence interval (CI), p < 0.0001; Gp 2: 2.1, 1.6-2.9, p < 0.0001, Reference (Ref) Gp 5), ASA (S2: 1.3, 1.06-1.6, p < 0.01; S3 and greater: 3.02, 2.2-4.1, p < 0.0001, Ref S1), Procedure (EGD only: 1.9, 1.3-2.6, p <0.0002, both EGD & Col: 2.2,1.5-3.2, p <0.0001, Ref Col only), presence of CMC (Metabolic/Genetic: 2.3, 1.6 – 3.3, p <0.0001, Resp-Lower Airway: 1.3, 1.01-1.72, p= 0.04, Ref No CMC) were predictors of higher AE. Conclusions: In the selected data set from the PSRC, the overall AE rate was 4.8%. Our analysis indicates that younger age, higher ASA status, EGD procedure, and presence of certain CMC were independent predictors of higher AE. The majority of such AE were minor and reversible with none of them leading to death or disability when performed in institutions with well-organized sedation systems that were able to quickly recognize and rescue at risk patients.

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

▪ IntroductionCLL11 is a large randomized phase 3 trial investigating first-line chemoimmunotherapy in CLL patients with comorbidities, i.e. patients typically treated in daily practice. Here, we present:(i) The final stage 2 analysis with efficacy and safety results of the head-to-head comparison between GA101 plus Clb (GClb) and rituximab plus Clb (RClb); at the pre-planned interim analysis, the primary endpoint was met early and the results were released by the independent data monitoring board.(ii) An update on the stage I analysis (GClb vs. Clb and RClb vs. Clb comparisons) with longer observation time; the final stage 1 analysis recently showed that GClb or RClb has superior efficacy to chemotherapy with Clb alone. MethodsTreatment-naïve CLL patients with a Cumulative Illness Rating Scale (CIRS) total score >6 and/or an estimated creatinine clearance (CrCl) <70 mL/min were eligible. Patients received Clb alone (0.5 mg/kg po d1, d15 q28 days, 6 cycles), GClb (100 mg iv d1, 900 mg d2, 1000 mg d8, d15 of cycle 1, 1000 mg d1 cycles 2-6), or RClb (375 mg/m2 iv d1 cycle 1, 500 mg/m2 d1 cycles 2-6). Primary endpoint was investigator-assessed progression-free survival (PFS). Response rates, minimal residual disease (MRD), and overall survival (OS) were key secondary efficacy endpoints. ResultsFinal results of the stage 2 analysis: Median observation time was 19 months. The GClb and RClb treatment arms were well balanced for baseline characteristics. Median age, CIRS score, and CrCl at baseline were 73 years, 8, and 63 mL/min respectively. Key efficacy and safety results are shown in the table. [Display omitted] The PFS benefit of GClb over RClb was supported by all pre-planned subgroup analyses (including the cytogenetic subgroups 17p-, 11q-, 12+, 13q-). The number of patients with MRD negative blood samples at end-of-treatment was more than 10-fold higher with GClb compared with RClb (63/214 [29.4%] vs. 6/243 [2.5%]). Grade 3-4 infusion-related reactions with GClb occurred at first infusion only.Updated results of the stage 1 analysis: Median observation time was 23 months. Confirming the primary stage 1 results, GClb or RClb compared with Clb alone was associated with statistically significant and clinically meaningful improvement in PFS (GClb vs. Clb: HR 0.18, CI 0.13-0.24, p<.0001, RClb vs. Clb: HR 0.44, CI 0.34-0.57, p<.0001). The updated median PFS in GClb, RClb and Clb were 26.7, 16.3 and 11.1 months, respectively. Updated OS analysis demonstrated a benefit of GClb over Clb (HR 0.41, CI 0.23-0.74, p=0.002). OS analysis for RClb over Clb showed HR 0.66, CI 0.39-1.11, p=0.113. At the data cut-off, 9%, 15%, and 20% of the patients in the GClb, RClb, and Clb arms, respectively, had died. OS medians were not reached. ConclusionsGA101, a novel, glycoengineered, type II CD20 antibody, in combination with Clb (GClb regimen) demonstrated statistically significant and clinically meaningful prolongation of PFS, and higher complete response rate and MRD negativity rate compared with RClb in previously untreated CLL patients with comorbidities. Infusion-related reactions and neutropenia were more common with GClb without an increase in infections. Furthermore, GClb vs. Clb alone demonstrated a prolongation of OS. Overall, GClb is superior to RClb and a highly active treatment in this typical CLL patient population. Disclosures:Goede:Mundipharma: Honoraria; F. Hoffmann-La Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Off Label Use: GA101 is a novel, glycoengineered, type II anti-CD20 monoclonal antibody that is designed to enhance direct cell death and antibody-dependent cellular cytotoxicity. It is being investigated in chronic lymphocytic leukemia, Non-Hodgkin's Lymphoma and other hematologic indications. Fischer:Mundipharma: Travel grants, Travel grants Other; F. Hoffmann-La Roche: Travel grants Other. Engelke:F. Hoffmann-La Roche: Travel grants Other. Eichhorst:Mundipharma: Honoraria, Research Funding; Janssen: Honoraria; Celgene: Consultancy; F. Hoffman-La Roche: Honoraria, Research Funding. Wendtner:F. Hoffmann-La Roche: Consultancy, Research Funding. Dilhuydy:F. Hoffmann-La Roche: Consultancy. Opat:F. Hoffmann-La Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Alexion Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Novartis Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees. Owen:F. Hoffmann-La Roche: Honoraria. Kreuzer:F. Hoffmann-La Roche: Consultancy, Honoraria. Langerak:F. Hoffmann-La Roche: Research Funding. Ritgen:F. Hoffmann-La Roche: Research Funding. Stilgenbauer:F. Hoffmann-La Roche: Consultancy, Honoraria, Research Funding. Asikanius:F. Hoffmann-La Roche: Employment. Humphrey:F. Hoffmann-La Roche: Employment. Wenger:F. Hoffmann-La Roche: Employment, Ownership interests (including stock options) in a start-up company, the stock of which is not publicly traded Other. Hallek:F. Hoffmann-La Roche: Consultancy, Honoraria, Research Funding.

The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer

Aging is associated with a reduced capability of the immune system to adequately respond to pathogens and to prevent tumor formation. As a consequence of immunosenescence, older people have a higher risk to develop infections as well as cancer. In addition, cancer itself may expose old patients to infections, including opportunistic infections, i.e. Pseudomonas aeruginosa, Aspergillus fumigatus and Cytomegalovirus infection. Patients with hematologic malignancies have a higher risk than patients with solid tumors, because of more prolonged disease-related and treatment-related neutropenia and intensive immunosuppressive regimens. Co-existing medical conditions, e.g. chronic renal failure, diabetes mellitus, emphysema, which are quite common in the elderly, may also contribute to rising the infectious risk, as well as the use of long term vascular catheters, which is required in a large number of cancer patients to administrate chemotherapy. Neutropenic infections do not only represent a major cause of morbidity and mortality, but may be responsible for a reduction of the antineoplastic treatment dose and dose intensity, thus compromising the overall treatment effectiveness. The use of antibiotic prophylaxis to reduce neutropenia-related infectious complications in patients with cancer is still object to debate. Quinolones represent the most attractive option, since these drugs have a broad antimicrobial spectrum, systemic bactericidal activity, good tolerability and lack of myelosuppression. However, fluoroquinolone prophylaxis has already been associated with the emergence and spread of resistant bacteria and strictly precludes the subsequent use of fluoroquinolones for initial empirical therapy; in addition, fluoroquinolones should be administered with caution among elderly patients, especially those with more pronounced vascular or degenerative impairment of the central nervous system, cardiac disease or electrolyte disturbances.

ACOG Practice Bulletin No. 73: Use of Hormonal Contraception in Women With Coexisting Medical Conditions

ACOG Practice Bulletin No. 73: Use of Hormonal Contraception in Women With Coexisting Medical Conditions

Does routine child health surveillance contribute to the early detection of children with pervasive developmental disorders? An epidemiological study in Kent, U.K.

BackgroundRecently changed guidelines for child health surveillance in the United Kingdom (U.K.) suggest targeted checks only, instead of the previously conducted routine or universal screening at 2 years and 3.5 years. There are concerns that these changes could lead to a delay in the detection of children with autism and other pervasive developmental disorders (PDD). Recent U.K. studies have suggested that the prevalence of PDD is much higher than previously estimated. This study establishes to which extent the routine checks contributed to the early detection and assessment of cases of PDD. Simultaneously we have evaluated the process involved and estimate the prevalence of PDD in our district.MethodsRetrospective study design utilising community medical files. Headteachers of schools (n = 75) within Maidstone district (Kent) were asked to report all children with an established diagnosis of autism or PDD attending year 4 (born '91 and '92 / n = 2536) in October 2000 based on educational records.Results59 schools (78.7%) took part in the study. A total of 33 children were reported. 21 fulfilled the inclusion criteria (12 falsely reported). The prevalences were (per 10,000): PDD 82.8 (male to female ratio 6:1), childhood autism 23.7, Asperger's syndrome 11.8 and autistic spectrum disorder 47.3. Co-existing medical conditions were noted in 14.3%; 52.4% were attending mainstream schools. In 63.2% of cases concerns – mainly in the area of speech and language development (SLD) – had been documented at the 2 year check. At the 3.5 year check concerns were noted in 94.1% – the main area was again SLD (76.5%), although behavioural abnormalities were becoming more frequent (47.1%). A total of 13 children (68.4%) were referred for further assessment as a direct result of the checks.ConclusionsThe prevalences for different types of PDD were similar to figures published recently, but much higher than reported a few years ago. Analysis of our data suggests that routine surveillance is a valuable contributing factor for the early detection of PDD and thereby facilitates early intervention. Thus, if routine surveillance ceases, then an alternative method of early detection should be put in place.

Suitability of children for ENT day case procedures.

This prospective study evaluates the suitability of 500 children under 12 years of age using both medical and social criteria, to determine the proportion of children suitable for increasing the scope of ENT operations performed as day cases. Co-existing medical conditions that could interfere with both surgery and anaesthesia were found in 39 (8%). A combination of adverse social and domestic conditions, including the number of adults and children resident, number of bedrooms and individuals sleeping in the child's bedroom, the number of cars, and the presence of a telephone, were present in 171 (34%) of children's homes and were almost exclusively found in National Health Service (NHS) patients. Private patients, 31 (6%) were more suitable for day surgery. Guidelines need to be followed to minimize the risk if the number of procedures is increased, if more patients were treated privately, the proportionate number of patients requiring in patient care would rise in the National Health Service (NHS).

ACE inhibitors. Differential use in elderly patients with hypertension.

High blood pressure (BP) in the elderly must not be ignored as a normal consequence of aging. The criteria for the diagnosis of hypertension and the necessity to treat it are the same in elderly and younger patients. The aim of treatment of elderly hypertensive patients is to decrease BP safely and to reduce risk factors associated with cerebrovascular, cardiovascular and renal morbidity and mortality. The treatment of elderly hypertensive patients should be adjusted according to the needs of the individual, based upon age, race, severity of hypertension, co-existing medical problems, other cardiovascular risk factors, target-organ damage, risk-benefit considerations and costs. In addition to the elevated BP, other cardiovascular risk factors include smoking, glucose intolerance, hyperinsulinaemia, dyslipidaemia, hypercreatininaemia, peripheral vascular disease, left ventricular hypertrophy, and microalbuminuria (or albuminuria). Thus, the choice of initial antihypertensive therapy in elderly hypertensive patients should be based not only on the expected response, but also on the effects of therapy on lipid, potassium, glucose and uric acid levels, and left ventricular anatomy and function. Co-existing medical conditions (such as asthma, diabetes mellitus, heart failure, renal failure, gout, coronary artery disease, hyperlipidaemia and peripheral vascular disease) are major determinants for the selection of antihypertensive medications. With previous therapies (diuretics, beta-blockers, etc.), good BP control in the elderly was associated with clear and statistically significant reductions in stroke-related morbidity and mortality, but the overall effects on cardiovascular and renal complications of hypertension was either more variable or less obvious. Angiotensin converting enzyme (ACE) inhibitors are not only efficacious antihypertensive agents in the elderly, but also appear promising in counteracting some of the cardiovascular and renal consequences of hypertension. They are well tolerated and have a relatively low incidence of adverse effects. ACE inhibitors possess ancillary characteristics that are potentially beneficial for many elderly patients, including reduction of left ventricular mass, lack of metabolic and lipid disturbances, no adverse CNS effects, no risk of induction of heart failure, and a low risk of orthostatic hypotension. Since ACE inhibitors may improve perfusion to the heart, kidney and brain, they are well worth considering for the treatment of elderly patients with hypertensive target organ damage, especially in patients with heart failure, and diabetic patients with early nephropathy.

Treatment of hypertension with felodipine in patients with concomitant diseases.

Coexisting medical conditions often complicate the selection of antihypertensive drugs. Felodipine, a new vascular-selective calcium antagonist with demonstrated antihypertensive efficacy, has not been found to alter lipid profiles in hypertensive patients. Studies in additional patient populations have yielded insights into the effects of the drug on other diseases that may coexist with hypertension. In individuals with stable angina pectoris or congestive heart failure, acute administration of felodipine reduces systemic vascular resistance and increases cardiac output and total coronary blood flow; myocardial contractility is not depressed at doses that produce a clinically significant reduction in vascular resistance. In patients with coronary stenoses, the drug increases vessel diameter in the vicinity of obstructive lesions. Single-dose and long-term studies in patients with exertional angina have found that felodipine reduces anginal frequency and improves exercise tolerance. In patients with congestive heart failure, chronic dosing with felodipine produces a persistent reduction in vascular resistance and an increase in cardiac output, both at rest and during exercise. Symptomatic improvement and increased exercise tolerance have been noted in some studies. In patients with Raynaud's phenomenon, felodipine has been associated with a dose-dependent improvement in symptomatology. Among individuals with exercise-induced bronchospasm, the drug has no effect on resting bronchial tone and may exert some positive effects during exercise. In hypertensive patients with Type II diabetes, felodipine has not been found to raise glucose levels significantly. The data obtained thus far suggest that felodipine is safe for use in hypertensive patients with a variety of concomitant diseases.